Latest Biotech News

Beam Therapeutics announced a liver‑targeted base‑editing program, BEAM‑304, designed to correct prevalent PAH gene mutations that cause phenylketonuria (PKU). Beam plans to pursue multiple...

Researchers at Northwestern reported HYDRACs—heterobifunctional proteomimetic polymers that recruit cellular degradation machinery to remove previously “undruggable” oncoproteins such as MYC and...

Ultima Genomics struck an agreement with Hamilton to automate sample preparation and amplification workflows on Hamilton’s Microlab Star platform, supporting scale‑up of Ultima’s high‑throughput...

The Advanced Research Projects Agency for Health (ARPA‑H) designated up to $144 million for anti‑aging research, funding teams to study markers and interventions for healthy longevity and...

UC‑Davis researchers introduced Chromatin HiFi (CiFi), a protocol combining chromatin conformation capture with PacBio HiFi long reads to generate richer, long‑range chromatin interaction maps and...

A study published in Science linking the gut microbiome to the efficacy of PD‑1 immunotherapy in epithelial tumors has been awarded the Bial Award in Biomedicine and its €350,000 prize. The work...

Novo Nordisk signed a collaboration and licensing agreement with Vivtex that could total up to $2.1 billion in payments to develop oral formulations of peptide and protein therapies for obesity,...

GSK agreed to acquire 35Pharma for $950 million in cash to secure HS-235, a protein‑based candidate poised for pulmonary hypertension (PH) studies, the companies said. HS‑235 completed a Phase I...

GSK licensed two small interfering RNA (siRNA) assets from Frontier Biotechnologies in a deal that starts with a $40 million up‑front payment and can reach roughly $1 billion with milestones, the...

Gilead Sciences and Merck each reported data updates as they push forward novel daily HIV oral therapies while also exploring a longer‑acting weekly pill in partnership, the companies said. Both...

Apheris announced the ADMET Network, a federated data initiative enabling pharmaceutical companies to collaboratively train ADMET (absorption, distribution, metabolism, excretion, toxicity)...

Samsung Biologics will join the Coalition for Epidemic Preparedness Innovations (CEPI) Vaccine Manufacturing Facility Network to create a ‘ready‑to‑activate’ recombinant‑protein vaccine...

Gilead moved to strengthen its cell therapy presence with the acquisition of Arcellx, a deal public reports put at roughly $7.8 billion, positioning the company to compete with established CAR‑T...

Pfizer exercised an option to secure global licensing rights to Beam Therapeutics’ liver‑targeted gene‑editing candidate after Beam’s strategic shift away from in‑house gene therapy...

An international proteomics team led by Matthias Mann and Jakob Bader identified 22 cerebrospinal‑fluid protein markers for multiple sclerosis (MS) using high‑throughput liquid...

Northwestern University researchers reported HYDRACs—heterobifunctional proteomimetic polymers (protein‑like polymers)—that bind oncogenic proteins MYC and KRAS and recruit cellular degradation...

Gilead Sciences agreed to acquire Arcellx in a $7.8 billion transaction that brings the BCMA‑directed CAR‑T therapy anito‑cel fully under Gilead’s control. The deal consolidates development and...

Beam Therapeutics launched BEAM‑304, a liver‑targeted base‑editing program designed to correct common PAH mutations that cause phenylketonuria (PKU), and signaled intent to file an IND in 2026....

Novo Nordisk announced a dramatic cut to list prices for its GLP‑1 medicines, moving Wegovy and Ozempic to a $675 monthly list price beginning in 2027, aimed at patients with high deductibles and...

GlaxoSmithKline agreed to acquire Canadian biotech 35Pharma for $950 million in cash to obtain HS235, a protein‑based investigational therapy targeting activin receptor signalling with potential...